LexaGene Introduces its Commercial Product MiQLab

Automated, genetic analyzer designed for rapid, point-of-need testing

BEVERLY, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops genetic analyzers for rapid pathogen detection, is pleased to announce the name and first look of the Company’s flagship product, called MiQLab, which can be seen on the Company’s website, and is being manufactured for an anticipated commercial launch prior to the end of September 2020.

As announced, LexaGene will be hosting a webinar to provide additional information as well as a general corporate overview at 2 PM EST on July 14, 2020.  All are invited to register for the webinar at this link: https://event.webcasts.com/starthere.jsp?ei=1294081&tp_key=b029bb1 ....

Dr. Jack Regan, LexaGene’s CEO and Founder, states, “We started this company with a vision to create a technology that the world needs, particularly during these difficult times as we struggle to contain the spread of COVID-19. We have finished incorporating the feedback from beta testing and have begun manufacturing our commercial instrument, the MiQLab genetic analyzer. It is extremely gratifying to be so close to the start of selling this much-needed technology.” 

MiQLab is a fully automated genetic analyzer that is designed to deliver reference-quality data at the point-of-need. MiQLab’s technology screens samples for up to 27 different targets at once—looking for pathogens and/or antimicrobial resistance factors—and returns results in approximately one hour. It is designed to be operated at the site of sample collection to avoid the delay associated with shipping and manually processing samples. This technology is designed for use in multiple markets, including human and veterinary diagnostics, as well as food safety testing ($12.9B¹, $2.2B², and $23.4B³ markets, respectively).

MiQLab is open-access, which allows users to customize their tests easily. We have done extensive research and found no commercially available point-of-need instruments that allow for easy assembly and performance of highly multiplexed tests. As such, we’ve concluded no comparable technology exists on the market today, providing LexaGene a unique opportunity to target this market, which is valued at $20B^4-7. Scientists who have custom testing needs make up the open-access market, and they currently spend hours a day to manually perform PCR testing. These same individuals will now have the opportunity to save hours a day by having MiQLab automate the processing of their own tests.